64Cu-TETA-octreotide

N/A

Report date: 2025/11/20 16:03:43

NME

Base Information

Drug Name64Cu-TETA-octreotide

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSomatostatin receptor 2 binders

TargetsSomatostatin receptor 2

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesWashington University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWashington University School Of Medicine

Active IndicationsN/A

Inactive IndicationsNeuroendocrine Tumors

Other Information

ATC CodeN/A